ABSTRACT: The evasion of apoptosis is a key characteristic of cancer, and thus strategies to selectively induce apoptosis in cancer cells hold considerable promise in personalized anticancer therapy. Structurally similar procaspase activating compounds PAC-1 and S-PAC-1 restore procaspase-3 activity through the chelation of inhibitory zinc ions in vitro, induce apoptotic death of cancer cells in culture, and reduce tumor burden in vivo. Ip or iv administrations of high doses of PAC-1 are transiently neurotoxic in vivo, while S-PAC-1 is safe even at very high doses and has been evaluated in a phase I clinical trial of pet dogs with spontaneously occurring lymphoma. Here we show that PAC-1 and S-PAC-1 have similar mechanisms of cell death induction at low concentrations (less than 50 μM), but at high concentrations PAC-1 displays unique cell death induction features. Cells treated with a high concentration of PAC-1 have a distinctive gene expression profile, unusual cellular and mitochondrial morphology, and an altered intracellular Ca 2+ concentration, indicative of endoplasmic reticulum (ER) stress-induced apoptosis. These studies suggest strategies for anticancer clinical development, specifically bolus dosing for PAC-1 and continuous rate infusion for S-PAC-1.
■ INTRODUCTION
The discovery of compounds that induce apoptotic cell death is a major aim of anticancer drug discovery. As cancer cells characteristically evade apoptosis through inactivating mutations and aberrant expression levels of key proteins, the challenge is to reactivate the apoptotic cascade, or to exploit those parts that remain functional. 1, 2 Among the current arsenal of compounds that target the apoptotic pathway are small molecule disruptors of the p53-MDM2 interaction, 3, 4 inhibitors of Bcl-2, 5 and ligands for XIAP. 6 Since major apoptotic pathways converge on the activation of executioner caspases-3/-7 from their less active procaspase zymogens, one appealing apoptosis-inducing strategy is the direct activation of executioner procaspases with a small molecule, bypassing defective upstream apoptotic circuitry. Procaspase-3 levels are elevated in many tumor types compared to normal tissue, 7−13 therefore a procaspase-3 activating compound could have value as a selective personalized anticancer drug. To date, the first discovered procaspase-activating compounds are procaspase-3/-7 activators PAC-1, 14−16 S-PAC-1, 17 other PAC-1 derivatives, 18, 19 and procaspase-3/-6 activator 1541. 20, 21 PAC-1 and its sulfonamide derivative S-PAC-1 activate procaspase-3 in vitro through the chelation of inhibitory zinc ions, 15, 17, 18 induce apoptotic death in cultured cancer cells selectively, 14, 17 and are effective in murine tumor models and pet dogs with lymphoma. 14, 16, 17 In cancer cells, a fluorescent derivative of PAC-1 colocalizes with sites of caspase-3/-7 activity, suggesting that PAC-1 acts to chelate labile inhibitory Zn 2+ from procaspase-3/-7 in the cell to induce apoptotic death. 18 When administered via ip or iv injection, high doses of PAC-1 elicit transient neuroexcitation (seizure and ataxia) in mice and dogs, thus S-PAC-1 was developed as a viable procaspase activator for in vivo therapeutic use. 17 This compound is well tolerated at doses in excess of 350 mg/kg and 60 mg/kg in mice and dogs, respectively, and showed promising results in a small phase I clinical trial of pet dogs with lymphoma. 17 As PAC-1 and S-PAC-1 elicit drastically different neurologic responses in vivo, we sought to further characterize similarities and differences between PAC-1 and S-PAC-1 in an effort to understand how each compound can be best utilized in anticancer therapy. In this work, we report further mechanistic similarities between low concentrations (<50 μM) of PAC-1 and S-PAC-1 but differences at high concentrations, suggesting different dosing strategies and anticancer applications for each compound.
■ EXPERIMENTAL SECTION
Cell Lines and Reagents. All cell lines were purchased from ATCC, grown in a 37°C, 5% CO 2 , humidified environment, in media containing 1% penicillin/streptomycin. Cell culture conditions are as follows: human cell lines U-937 lymphoma and HeLa cervical cancer in RPMI 1640 or DMEM with 10% fetal bovine serum (FBS), HL-60 human leukemia in IMEM with 20% FBS, and Neuro-2a murine neuroblastoma cells in EMEM with 10% fetal calf serum (FCS). PAC-1 and S-PAC-1 were synthesized as previously reported. 14, 17 The following compounds were purchased: thapsigargin (Tg, Santa Cruz Biotechnology), N,N,N′,N′-tetrakis(2-pyridylmethyl)ethylenediamine (TPEN, Sigma), and digitonin (Calbiochem). Compounds were dissolved in DMSO (Sigma) for cell culture studies, or 2-hydroxypropyl-β-cyclodextrin (HPβCD, CDT) for cell permeability and blood−brain barrier studies.
Cellular Zn 2+ and Ca 2+ Measurements. The following genetically encoded FRET sensors were used in this study: ZapCY2 was used to study cytosolic Zn 2+ , 22 D3cpv for cytosolic Ca 2+ , 23 and D1ER for ER Ca 2+ levels. 24 HeLa cells were transfected with sensor constructs in 3.5 cm glass bottom imaging dishes using TransIt (Mirus), 1 μg of DNA:5 μL of TransIt, and imaged 48 h post-transfection with an Axiovert 200 M inverted fluorescence microscope (Zeiss) with a 1.3NA 40× oil immersion objective, and a Cascade 512B CCD camera (Roper scientific), equipped with a Xenon arc lamp (XBO75). To study cytosolic Zn 2+ , cells were imaged in phosphate-free HEPES-buffered Hanks balanced salt solution (HHBSS), pH = 7.4 to prevent precipitation of zinc. At the end of each experiment, cells were treated with 150 μM TPEN, followed by 10 μM digitonin and a Zn 2+ /EGTA buffered solution with free Zn 2+ buffered at 9.5 nM. These perturbations allow determination of low and high FRET ratios, respectively. The 9.5 nM Zn 2+ solutions were made from Zn 2+ /EGTA-buffered solutions, as described. 22 To study cytosolic Ca 2+ , cells were imaged in HEPES-buffered Hanks balanced salt solution (HHBSS), pH = 7.4. At the end of each experiment, cells were treated with 5 μM ionomycin and 10 mM CaCl 2 to identify the maximum FRET ratio of the sensor. Details regarding image acquisition and analysis are in the Supporting Information. All experiments were conducted at least three times. Statistical analysis was performed using ANOVA with a post hoc test or Student's t test using KaleidaGraph.
Gene Expression Profiling and Connectivity Map Analysis. U-937 or HL-60 cells (3,000,000 cells/sample) were incubated in the presence of 25 μM PAC-1 or S-PAC-1, 100 μM PAC-1, or DMSO vehicle (0.2% final DMSO v/v) for 6 h in a 12-well plate in culture media for the respective cell lines as described above. Following RNA isolation, whole genome transcript profiling was performed on the Illumina HumanHT-12 bead array for compounds and DMSO control from three independent experiments. Data processing and comparison to the Connectivity Map database were all performed exactly as previously reported 25 and are described in more detail in the Supporting Information.
Transmission Electron Microscopy (TEM) and Confocal Microscopy. U-937 cells were harvested and transferred to a 24-well plate at 500,000 cells/well in 500 μL of RPMI 1640 medium with 10% FBS. DMSO, PAC-1, or S-PAC-1 was dissolved from DMSO stocks in RPMI 1640 with 10% FBS as premixed concentrated solutions. Compound solutions of 500 μL were added to the wells with cells, so that the final concentration of compound was 100 μM PAC-1, 100 μM S-PAC-1 (in 1% v/v DMSO), or DMSO for a compound exposure of 1, 2, and 3 h. The cells were washed once with PBS and pelleted. Karnovsky's fixative (500 μL/sample) was filtered through a 0.22 μm filter, and fixative was added directly to the cell pellet. The preparation and imaging of samples by TEM were carried out in part by the Center for Microanalysis of Materials of the Frederick Seitz Materials Research Laboratory Central Facilities, University of Illinois. Images of several cells in each sample were taken by film and scanned. Shown are representative cell images over three experiments.
HeLa cells were harvested and grown in Lab-Tek 4-well chambered 1.0 borosilicate coverglass (Nunc) dishes to ∼50% confluency in RPMI 1640 media. The cells were washed with Hanks balanced salt solution (HBSS). The cells were treated with 25 and 100 μM PAC-1, 100 μM S-PAC-1, and 10 μM thapsigargin premixed in 500 μM HBSS for exposure times up to 12 h, and stained with Mitotracker Red CMXRos (Invitrogen) and SYBR Green I (Invitrogen) in HBSS. For details regarding order of treatment and staining, see the Supporting Information. The cells, in 500 μL of HBSS, were imaged on a LSM700 confocal microscope (Zeiss) using a 40× oil immersion objective. Shown cell images are representative of the cell population over at least three experiments. Cell viability was diagnostically assessed by flow cytometry via FITC−annexin V and propidium iodide as described in the Supporting Information.
Cell Cytotoxicity. U-937 cells were harvested, and 500,000 cells/sample were exposed to DMSO for 1 h, and 100 μM PAC-1 or S-PAC-1 (as described above for transmission electron microscopy experiments) for exposure times of 4, 8, 12 , and 24 h. Following compound exposure time, the cells were centrifuged in the 24-well plate, washed once in 500 μL of RPMI 1640, centrifuged again, and resuspended in 500 μL of RPMI 1640. At 24 h, cell viability was assessed by annexin V/ propidium iodide (AV/PI) double staining and flow cytometry. Data collected from at least 10,000 cells was analyzed using the BD FACSDiva Software, with percentage of whole cells with negative staining for FITC−annexin V and propidium iodide reported as viable cells. The percentage of viable cells was averaged over three replicate experiments; statistical analysis was performed as a Student's t test in Excel.
Neuronal Cell Permeability Assay and Blood−Brain Barrier (BBB) Penetration Study. Neuro-2a cells were grown to ∼80% confluence in 10 cm culture dishes and were detached with trypsin−EDTA and suspended in EMEM with 10% FCS. Cells were centrifuged, washed twice with chilled PBS, then resuspended in serum free media containing 50 μM PAC-1 or S-PAC-1 dissolved in HPβCD to a final volume of 10 mL in conical tubes and gently agitated on a laboratory orbital shaker set at 40 rpm and 37°C for 30 min. Cells were washed with chilled PBS and centrifuged, and residual supernatant was removed three times. Resultant cell pellets were lysed with 1 mL of M-PER and centrifuged, and residual cell lysates were collected and analyzed by HPLC for PAC-1 or S-PAC-1 concentrations. Experiments were conducted in triplicate; statistical analysis was performed as a Student's t test in Excel.
BBB penetration study was performed as follows: 12 week old, female, C57/BL6 mice were administered PAC-1 or S-PAC-1 in HPβCD at 75 mg/kg via lateral tail vein injection. Five minutes post lateral tail vein injection, mice were sacrificed, and blood was collected by lacerating the right auricle with iris scissors. An 18 gauge angiocatheter was inserted through the left ventricle, and all residual circulatory volume was removed by perfusing 3.6 mL of 0.9% saline solution over 6 min via an analog peristaltic pump. Brains were harvested from the cranial vault, weighed, and homogenized in 3 mL of ice cold methanol. Homogenized samples were centrifuged at 4000 rpm for 10 min and supernatant and tissue debris separated. The resultant supernatant was then centrifuged at 10,000 rpm for an additional 10 min, and clarified supernatants (3 mL) were analyzed, along with serum, by HPLC to determine compound concentrations. Experiments were conducted in triplicate; statistical analysis was performed as a Student's t test in Excel.
■ RESULTS

Effect of PAC-1 and S-PAC-1 on Intracellular Zn
2+
Concentration. PAC-1 and S-PAC-1 ( Figure 1a ) have been shown to activate procaspase-3 in vitro through the chelation of inhibitory zinc ions, 15, 17, 18 and both compounds chelate zinc with comparable K d values (52 nM for PAC-1 and 46 nM for S-PAC-1); 17, 18 however, the effect of these compounds on the cellular zinc pool has not been examined. Genetically encoded Zn 2+ sensors have been developed to study changes in intracellular Zn 2+ concentrations in live cells. 22, 26 A conformational change in the sensor upon Zn 2+ binding leads to increased fluorescence resonance energy transfer (FRET), offering an opportunity to visualize the changes in the cellular labile zinc pool upon treatment with PAC-1 or S-PAC-1. Zn 2+ levels are proportional to the FRET ratio (FRET/CFP signal), which can be measured by fluorescence microscopy. HeLa cells, transfected with the ZapCY2 sensor (apparent K d ′ for Zn 2+ : 811 pM), 22 were exposed to PAC-1 or S-PAC-1 for 15 min at 10 μM, the approximate concentration at which both compounds induce half-maximal cytotoxicity at 72 h in a variety of cell lines. 14, 17, 18 Upon treatment with either PAC-1 or S-PAC-1, the FRET ratio decreased, indicating a decrease in intracellular free Zn 2+ ( To demonstrate that the decrease in FRET was due to chelation of labile zinc, cells were washed and exposed to 150 μM TPEN, a cell permeable Zn 2+ chelator with a K d of 2.6 × 10 −16 M. 27 The FRET ratio of the sensor decreased further upon treatment with this powerful Zn 2+ chelator. Finally, when cells were permeabilized with digitonin and treated with a solution containing 9.5 nM Zn
, the FRET ratio of the sensor increased. Together, these experiments suggest that PAC-1 and S-PAC-1 penetrate cells and chelate intracellular Zn 2+ . Effect of PAC-1 on Global Gene Expression. Transcript profiling can be a useful tool for studying the effect of compounds on global gene expression, 28 and was thus used in the assessment of PAC-1 and S-PAC-1. First, mRNA was isolated from HL-60 cells that were treated with PAC-1 and S-PAC-1 (25 μM for each) for 6 h, and a transcript profile was generated. At this low concentration, PAC-1 and S-PAC-1 have a very similar pattern of up-and downregulated transcripts. DDIT4, IL8, STC2, JUN, SLC25A24, ATF3, and TNF were all among the most highly upregulated transcripts in both treatment groups compared to DMSO control (Figure 2a) . The Spearman rank correlation value, 29 a measure of similarity, is 0.928 for PAC-1 and S-PAC-1 profiles (using the top 200 upand downregulated genes). These results indicate that, at 25 μM, PAC-1 and S-PAC-1 act on cancer cells in a remarkably similar manner. The transcript profile for 25 μM PAC-1 was also carried out in U-937 cells, and the results largely matched those obtained in HL-60 cells; numerous significantly up-and downregulated genes with a p-value cutoff of 0.05 were shared between transcript profiles in the two cell lines ( Figure S1 in the Supporting Information).
In a second transcript profile experiment, the expression signature of cells treated with high (100 μM) and low (25 μM) concentrations of PAC-1 in U-937 cells were compared. The transcript profiles between 25 μM and 100 μM PAC-1 have a Spearman rank correlation value of 0.436, indicating that the expression signatures are quite different. When compared to vehicle-treated cells, only three genes, DDIT4, ATF3, and JUN, are shared in the top 30 most upregulated genes for both high and low PAC-1 treatments. TNF, which ranks among the top 30 most upregulated genes for 25 μM PAC-1-treated cells, is among the top 30 most downregulated transcripts in the 100 μM PAC-1 profile (Figure 2b ). The transcript profiling data also suggest potential pathways affected and mechanisms of action at the high concentration of PAC-1. Three of the top 10 most highly upregulated transcripts, DDIT3 (CHOP transcription factor), PI3KIP1 (PI3K interacting protein 1), and HERPUD1(Herp), are associated with ER stress and unfolded protein response (UPR) pathways. 30−32 As such, we hypothesized that, at high concentrations, PAC-1 may induce cell death via the ER stress pathway.
Further supporting this hypothesis is the similarity of the expression signatures of PAC-1 and thapsigargin using the Connectivity Map. The Connectivity Map database contains 7000 gene expression profiles representing about 1300 individual compounds. 33 In comparison with the expression signature of 100 μM PAC-1, thapsigargin was the top permuted compound from the database with the most similar gene expression signature (Table S1 in the Supporting Information). As a sarco/endoplasmic reticulum calcium ATPase (SERCA) inhibitor, thapsigargin induces ER stress as the ER calcium stores are depleted by an inhibition of the ability of the ER to pump Ca 2+ . 34 Thus, this similar profile to thapsigargin supports ER stress as a possible mechanism for PAC-1 at high concentrations.
Effect of PAC-1 on Cellular and Mitochondrial Morphology. Transmission electron microscopy (TEM) was utilized to study the effect of a high concentration of PAC-1 on general cellular morphology. U-937 cells were exposed to 100 μM PAC-1 or S-PAC-1 for 1−3 h. Following treatment, cells were immediately washed, fixed, and imaged by TEM.
Compared to DMSO control cells, the remarkable changes to cellular morphology upon 100 μM PAC-1 treatment include large lysosome-like structures surrounded with myelin-like membranes, dilated ER, and myelin-like inclusions or packaging in the mitochondria (Figure 3a −c, Figure S2b in the Supporting Information). A few cells undergoing apoptosis and an apoptotic body were observed in the 3 h 100 μM PAC-1 The morphological changes visualized by electron microscopy in PAC-1-treated cells, especially mitochondrial changes (Figure 3c , and Figure S2b in the Supporting Information), motivated further investigation of the effect of PAC-1 on mitochondrial morphology. HeLa cells were treated with 25 μM and 100 μM PAC-1, 10 μM thapsigargin (ER stress inducing compound), and 100 μM S-PAC-1. The mitochondria were stained with Mitotracker Red and visualized by confocal microscopy. After a 60 min exposure of 100 μM PAC-1 and 10 μM thapsigargin, the mitochondrial staining was localized and punctate, compared to the diffuse mitochondrial staining observed in untreated cells or cells treated with 25 μM PAC-1 or 100 μM S-PAC-1 (Figure 3d−h) . Punctate mitochondrial staining was noted with 100 μM PAC-1 treatment at exposure times as early as 30 min ( Figure S3a in the Supporting Information). Cell viability was diagnostically measured at the exposure times by cell flow cytometry of a sample population of 5,000 cells. Even at 12 h, when ∼50% of HeLa cells exposed to 25 μM PAC-1 and 100 μM S-PAC-1 remained viable, no changes in mitochondrial morphology were noted ( Figure  S3b −h in the Supporting Information). These data suggest that, at high concentrations, PAC-1 induces a unique general cellular morphology compared to control and S-PAC-1-treated cells. PAC-1, at a high concentration, also induces a mitochondrial phenotype similar to thapsigargin. The staining of mitochondria was diffuse and unaltered with a low concentration of PAC-1 or high concentration S-PAC-1, even at longer exposure times when the cell population was undergoing death, indicating that a high concentration of PAC-1 behaves very differently than it does at a lower concentration or compared to equimolar amounts of S-PAC-1. 2+ to demonstrate the maximum FRET ratio and confirm sensor functionality in each cell. (b) A greater decrease in the FRET ratio of genetically encoded ER calcium sensor D1ER was observed upon treatment of 100 μM PAC-1 compared to S-PAC-1 (average of at least 9 cells or n = 3 experiments) and (c) the absolute change in FRET value is shown to demonstrate that 100 μM PAC-1 elicits a significantly different ER calcium response than S-PAC-1. Error bars represent standard deviation, p < 0.0001. Effect of a High Concentration of PAC-1 on Cytosolic and ER Ca 2+ Concentration. The similarity of thapsigargin and high concentrations of PAC-1 in both the expression profile and mitochondrial morphology experiments suggests that both compounds may be acting by a similar mechanism. Thapsigargin is known to cause an increase in cytosolic Ca 2+ as the calcium stores in the ER are released. 34 Thus, we used genetically encoded calcium sensors to examine whether PAC-1 induced changes in cytosolic Ca 2+ levels in live cells. 23 Treatment of HeLa cells expressing the calcium sensor D3cpv with 100 μM PAC-1 in calcium-free media led to an increase in cytosolic Ca 2+ (Figure 4a) . A lower increase was observed upon treatment of the cells with 50 μM PAC-1 ( Figure S4a in the Supporting Information). However, under the same experimental conditions 100 μM S-PAC-1 showed no significant change in the FRET of the sensor (Figure 4a , Figure  S4 in the Supporting Information).
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The increase in cytosolic Ca 2+ induced by 100 μM PAC-1 was observed in the absence of extracellular calcium, suggesting that PAC-1 induced release of Ca 2+ from the ER. To test this hypothesis, a genetically encoded calcium sensor that localizes to the ER, D1ER, was used to measure calcium levels within the ER. 24 Treatment of HeLa cells with 100 μM PAC-1 for 15 min caused the FRET ratio of the ER-localized calcium sensor to decrease, indicating a decrease in ER Ca 2+ (Figure 4b,c) . A less significant decrease was noted for 100 μM S-PAC-1 treatments. Furthermore, compared to the decrease in ER Ca 2+ observed for 100 μM PAC-1-treated cells, 50 μM PAC-1 elicited a smaller decrease, while 10 μM PAC-1 elicited no marked decrease in ER Ca 2+ , indicating that this effect is most noted at high PAC-1 concentrations ( Figure S4b in the Supporting Information). Together, the data from both cytosolic and ER Ca 2+ sensors demonstrate that a high concentration of PAC-1, but not S-PAC-1, triggers a marked decrease in ER Ca
2+
, and a concomitant increase in cytosolic Ca
. The release of Ca 2+ from the ER is a distinct indicator and trigger of an acute ER stress response, and leads to ER stress-related apoptosis, 35, 36 indicating that PAC-1 may behave as an ER stress inducing compound at high concentrations.
Cell Permeability of PAC-1 and S-PAC-1. The divergent in vivo neuroexciation induced by PAC-1 and S-PAC-1 may be attributed to differences in the ability to penetrate neuronal cell membranes, or differences in BBB permeability. 17 To explore the first hypothesis, Neuro-2a murine neuroblastoma cells were treated with either PAC-1 or S-PAC-1 (both in HPβCD) at 50 μM for 30 min. Following compound exposure and cell lysis, the lysates were analyzed by HPLC for intracellular compound concentration. Both PAC-1 and S-PAC-1 were detected in the (Figure 5a ). These results demonstrate that both PAC-1 and S-PAC-1 are equally capable of penetrating neuronal cell membranes and, together with evidence that both compounds enter cells and chelate intracellular zinc (Figure 2 ), suggest that cell permeability does not play an essential role in the different in vivo neuroexcitation induced by the two compounds.
BBB Penetrance of PAC-1 and S-PAC-1. We previously hypothesized that the differences in the BBB permeability of PAC-1 and S-PAC-1 might contribute to the observed neuroexcitation induced by PAC-1 in vivo. 17 The calculated logBB is a predictive value based on the ClogP of a compound and its total polar surface area. 37, 38 The PAC-1 calculated logBB value is −0.07 (ratio of PAC-1 concentrations in brain:blood of 46:54), while S-PAC-1 has a calculated logBB value of −1.26 (ratio of S-PAC-1 concentrations in brain:blood of 4:96). 17 We performed an in vivo study of BBB penetrance in which two cohorts of four C57/BL6 mice were injected with 75 mg/kg PAC-1 or S-PAC-1 (both formulated in HPβCD) via the lateral tail vein and subsequently sacrificed 5 min postinjection. Immediately following sacrifice, both serum and perfused brain samples were submitted for HPLC analysis of PAC-1 and S-PAC-1 concentration. While PAC-1 and S-PAC-1 serum concentrations differed by approximately 2-fold (70.4 ± 20.7 μM versus 35.8 ± 6.8 μM, respectively), the concentration of PAC-1 in the brain was 62 times greater than that of S-PAC-1 in the brain (47.3 ± 5.4 ng/mg versus 0.76 ± 0.05 ng/mg tissue, respectively) (Figure 5b,c) . These data support the hypothesis that PAC-1 and S-PAC-1 have significantly different permeability to the BBB, as well as support the predictive power of the logBB calculations for these compounds. These results suggest that BBB penetration is a prerequisite for the observed transient neuroexcitation induced by PAC-1 when high concentrations are administered in vivo.
Effect of Exposure Time of PAC-1 on Cell Viability. Cell culture studies indicate that at high concentrations PAC-1 acts to induce cell death through an ER stress-related mechanism, in addition to procaspase activation. Additionally, PAC-1, when administered at high doses via ip or iv injection, induces transient neuroexcitation in vivo, setting it apart from S-PAC-1. 17 These studies prompted further investigation into the clinical implications of PAC-1 and S-PAC-1 as anticancer compounds. Previously, high concentrations of PAC-1 (50 and 100 μM) and S-PAC-1 (50 μM) were reported to induce cell death by apoptosis via the sequential staining of phosphatidylserine and nuclear DNA by AV/PI. 14, 17 An examination of the effect of PAC-1 exposure on cell viability in cultured cells lends information on potential dosing strategies of PAC-1 in vivo, especially in light of the additional ER stress-related mechanism by which PAC-1 at high concentrations induces cell death. Thus, U-937 cells were treated with 100 μM PAC-1, 100 μM S-PAC-1, and DMSO for various exposure times. After treatment, the cells were washed and incubated in fresh medium. At 24 h, the cells were stained with AV/PI to assess cell viability by flow cytometry. While PAC-1 and S-PAC-1 induce death with a similar potency in a 24-or 72-h continuous exposure, 17 at exposure times as short as 4 h, 100 μM PAC-1 induced large amounts of cell death as assessed at 24 h. Furthermore, this effect was not observed with 100 μM S-PAC-1 ( Figure 6 , Figure S5 in the Supporting Information). Since PAC-1 and S-PAC-1 have comparable cell permeability, as assessed in the Neuro2a cell permeability assay, the unique ability of short exposures of a high concentration of PAC-1 to induce potent cell death may be related to the additional ER stress-related mechanism of PAC-1. Furthermore, the capability of short exposures of highly concentrated PAC-1 to induce cell death suggests that a transient exposure of the compound may be sufficient in inducing cancer cell death when a high serum concentration of PAC-1 is achieved in vivo.
■ DISCUSSION
In this study, we report two major findings: (1) PAC-1 and S-PAC-1 at low concentrations (less than 50 μM) induce death through a similar mechanism, and at high concentrations, short exposures of PAC-1 kill cells potently through an ER stressrelated cell death mechanism. (2) PAC-1 and S-PAC-1 have similar cell membrane permeability, yet major differences in exposure times to induce cell death and BBB penetrance, leading to different clinical implications. At low concentrations (50 μM or lower), the evidence supports the hypothesis that PAC-1 and S-PAC-1 serve as zinc-chelating procaspase activating compounds in the cell. In addition to their ability to activate procaspase-3 and induce apoptotic death, PAC-1 and S-PAC-1 have comparable zinc-binding K d values and cytotoxic IC 50 values. 17, 18 In this study, low concentrations of PAC-1 and S-PAC-1 elicit highly correlated transcript profiles in cells and cause a decrease in intracellular zinc concentrations. These observations contribute additional evidence that both compounds chelate labile zinc to activate procaspase-3 in the cell.
High Concentration PAC-1 as an ER Stress Inducing Compound. Evidence presented herein suggests that, at high concentrations, PAC-1 induces cell death through a mechanism that is related to ER stress, in addition to its ability to activate procaspase-3/-7 via zinc chelation. A high concentration of PAC-1 produces a distinct gene expression signature that is highly similar to ER stress inducer thapsigargin. Cellular morphology is altered in cells treated with a high concentration of PAC-1, in particular the dilated ER 39, 40 and enlarged lysosomes, indicative of an ER stress-related response. 41 The release of Ca 2+ through thapsigargin treatment has been shown to promote the hemolytic fusion of multiple lysosomes into large lysosomes in fibroblasts. 42 Comparisons of mitochondrial morphology show that a high concentration of PAC-1 induces punctuate mitochondrial staining also observed in thapsigargin treatment, as shown in Figure 4 and in other studies. 43, 44 The rapid mitochondrial changes may be due to mitochondrial Ca 2+ uptake, leading to release of cytochrome c and apoptosis through apoptosome formation, 45−47 and this has been observed in thapsigargin treatment. 48 Furthermore, Seervi and co-workers recently observed cytochrome c release in cells treated with high concentrations of PAC-1 independent of bax, bak, bcl-2, and bcl-xL expression, supporting our hypothesis that mitochondrial release of cytochrome c may be induced through ER stress; importantly, Seervi observed no cytochrome c release in cells treated with low (<30 μM) concentrations of PAC-1. 49 Data presented herein show that PAC-1 at high concentrations causes an increase in cytosolic calcium concentration within minutes of treatment, a hallmark of many ER stress inducing compounds, including thapsigargin 34 and tunicamycin. 50 Since ER stress inducing compounds thapsigargin (SERCA inhibitor) and tunicamycin (N-linked protein glycosylation inhibitor) have different targets yet share similar ER stressrelated phenotypes, it is possible that a high concentration of PAC-1 elicits a similar ER stress-related phenotype by acting at a completely different target than thapsigargin and tunicamycin. Furthermore, caspases have been found to be directly associated with the ER during the UPR pathways. For example, caspase-8 is thought to cleave ER membrane protein BAP31 to induce a release of Ca 2+ from the ER, 51, 52 procaspase-12 may accumulate and activate near the ER in the IRE1 pathway, 53 or executioner procaspase-7 may activate procaspase-12 near the ER. 46 ER stress may also induce caspase-2 cleavage of BID. 54 The induction of ER stress holds strong potential as an anticancer strategy. It has been proposed that cancer cells are already in a general state of ER stress due to accumulation of mutated and misfolded proteins, hypoxic tumor environment, and general dysregulation of cellular homeostasis. 55 Therefore ER stress inducing compounds could cause a more acute stress response in tumor cells than normal cells. Indeed, ER stress inducers, such as tunicamycin and bortezomib, have been investigated as novel anticancer drugs as single entity agents or combined with other chemotherapeutics. 56−58 Therefore, PAC-1 at high concentrations may hold potential therapeutic promise in its role as an ER stress inducing compound.
Clinical Implications for Low and High Concentrations of PAC-1. Experiments revealing that PAC-1 has a significant BBB penetrance support the hypothesis that the more positive calculated logBB value for PAC-1 is a predictor of BBB permeability, as well as the hypothesis that ip or iv injection of high doses of PAC-1 elicits a transient neurologic response in vivo by crossing the BBB. Although the neurologic effect observed in vivo in mice and dogs is transient and not lifethreatening, 17 the therapeutic use of low concentrations of PAC-1 could be a viable anticancer strategy that avoids this phenotype altogether. 16 The studies reported herein suggest that at these low dosages PAC-1 acts primarily as a zinc chelating procaspase-3 activator.
The ability of 100 μM PAC-1 to induce potent cell death 24 h after a short compound exposure is likely linked to ER stress, as short treatments of thapsigargin 59 and tunicamycin 60 also have been shown to elicit a similar strong cytotoxic response. The sufficiency of short exposures of compound to trigger death is unusual, and can be an attractive feature of anticancer drugs, allowing the compound to be administered via a bolus dosing regimen instead of constant rate infusion. Short compound exposure also may decrease dosing frequency for patients if the drug has effective cytotoxicity with one bolus dose. For example, the frequency of dasatinib dosing was reduced for treatment of chronic myeloid leukemia after the discovery that the compound is cytotoxic and effective after short exposures. 61, 62 Although PAC-1 elicits a transient neurologic response in vivo, a high peak plasma concentration (>50 μM) of PAC-1 can be achieved in mice with a short bolus iv infusion of the compound with slight to moderate neurological response. 17 However, at high doses, PAC-1 most likely will act in its ER stress-related mode as an anticancer therapy.
S-PAC-1 has been pursued as an anticancer therapy in a phase I clinical trial for patient pet dogs with lymphoma. 17 The initial bolus dose of S-PAC-1 achieved a peak plasma concentration no greater than ∼70 μM in the patient dogs with a continuous infusion of a maintenance dose achieving a blood serum concentration less than 50 μM. The experiments reported herein confirm that, at these concentrations, S-PAC-1 acts as a zinc-chelating procaspase activating compound. Furthermore, should S-PAC-1 be used at higher doses in future studies, it is unlikely that the ER stress induction observed with high concentrations of PAC-1 will be a confounding issue for the clinical use of S-PAC-1.
In summary, at low concentrations PAC-1 and S-PAC-1 act as zinc-chelating procaspase-3 activators, and at high concentrations PAC-1 also induces death through an ER stress-related mechanism. However, PAC-1 more readily penetrates the BBB and elicits a transient neurologic response in vivo when given via ip or iv injection. An intriguing clinical candidate would combine the safety of S-PAC-1 and the cytotoxicity features of PAC-1: a next-generation PAC-1 derivative with a highly negative logBB that induces cancer cell death with short exposures. A compound with these properties could be a potent and effective antitumor agent, and the search for such a derivative is underway.
